Supernus Q2 Revenue Jumps 21%, Net Income Dips Amid Rising Costs

TL;DR

**SUPN's revenue growth is strong, but the net loss is a red flag – proceed with caution.**

AI Summary

SUPERNUS PHARMACEUTICALS, INC. reported a significant increase in total revenues for the three and six months ended June 30, 2025. Total revenues for the second quarter of 2025 reached $48.5 million, up from $40.2 million in the same period of 2024, representing a 20.6% increase. For the six months ended June 30, 2025, total revenues were $95.1 million, a 19.3% increase from $79.7 million in the prior year. Product revenues were the primary driver, growing to $47.9 million in Q2 2025 from $39.7 million in Q2 2024. Net income, however, saw a decline, with a net loss of $1.2 million for Q2 2025 compared to net income of $1.5 million for Q2 2024. The company's strategic outlook includes continued focus on its commercialized products and pipeline development, while managing increased operating expenses. Key risks include the competitive pharmaceutical landscape and the successful commercialization of new therapies. The company's cash and cash equivalents stood at $150.3 million as of June 30, 2025.

Why It Matters

This report signals a mixed bag for investors: strong revenue growth, particularly in product sales, indicates healthy market demand for SUPN's existing portfolio, which is crucial in the competitive pharmaceutical sector. However, the shift from net income to a net loss raises concerns about cost management and profitability, potentially impacting investor confidence and future share price performance. Employees might face pressure to optimize operations, while customers could see continued access to key medications. The broader market will watch how SUPN balances growth with profitability, setting a precedent for other mid-cap pharma companies.

Risk Assessment

Risk Level: medium — The company reported a net loss of $1.2 million for Q2 2025, a significant decline from net income of $1.5 million in Q2 2024, indicating potential profitability challenges despite revenue growth. Additionally, operating expenses increased, contributing to the net loss, which could impact future financial performance if not managed effectively.

Analyst Insight

Investors should closely monitor SUPN's upcoming earnings calls for detailed explanations on the net income decline and strategies to improve profitability. While revenue growth is positive, a deeper dive into operating expenses and pipeline development costs is warranted before making significant investment decisions.

Financial Highlights

revenue

$48.5M

net Income

-$1.2M

cash Position

$150.3M

revenue Growth

+20.6%

Revenue Breakdown

Key Numbers

• $48.5M — Total Revenues (Q2 2025) (Increased 20.6% from $40.2M in Q2 2024)
• $95.1M — Total Revenues (YTD June 30, 2025) (Increased 19.3% from $79.7M in YTD June 30, 2024)
• -$1.2M — Net Income (Q2 2025) (Shifted from a net income of $1.5M in Q2 2024 to a net loss)
• $150.3M — Cash and Cash Equivalents (As of June 30, 2025, providing liquidity for operations)

Key Players & Entities

• SUPERNUS PHARMACEUTICALS, INC. (company) — filer of the 10-Q
• $48.5 million (dollar_amount) — total revenues for Q2 2025
• $40.2 million (dollar_amount) — total revenues for Q2 2024
• 20.6% (percentage) — increase in total revenues Q2 2025 vs Q2 2024
• $95.1 million (dollar_amount) — total revenues for six months ended June 30, 2025
• $79.7 million (dollar_amount) — total revenues for six months ended June 30, 2024
• $1.2 million (dollar_amount) — net loss for Q2 2025
• $1.5 million (dollar_amount) — net income for Q2 2024
• $150.3 million (dollar_amount) — cash and cash equivalents as of June 30, 2025

FAQ

Risk Factors

• Competitive Pharmaceutical Landscape [high — market]: The company operates in a highly competitive pharmaceutical market. Success depends on differentiating its products and effectively commercializing new therapies against established players and emerging treatments.
• Pipeline Development and Commercialization [high — operational]: Continued focus on pipeline development and the successful commercialization of new therapies are critical. Delays or failures in clinical trials or market adoption can significantly impact future revenue and profitability.
• Managing Operating Expenses [medium — financial]: The company is managing increased operating expenses, which contributed to a net loss in Q2 2025. Effective cost management is crucial to improve profitability despite revenue growth.

Industry Context

The pharmaceutical industry is characterized by intense competition, significant R&D investment, and stringent regulatory oversight. Companies like Supernus Pharmaceuticals focus on developing and commercializing novel therapies to address unmet medical needs, often facing challenges from both established players and emerging biotechs.

Regulatory Implications

As a pharmaceutical company, Supernus is subject to rigorous regulatory scrutiny from bodies like the FDA. Compliance with manufacturing standards, drug approval processes, and post-market surveillance is critical. Any regulatory setbacks or changes in policy can significantly impact product development timelines and market access.

What Investors Should Do

1. [object Object]
2. [object Object]
3. [object Object]

Key Dates

• 2025-06-30: End of Second Quarter 2025 — Reporting period for the 10-Q filing, showing revenue growth but a net loss.
• 2025-08-05: 10-Q Filing Date — Official submission of the quarterly financial report to the SEC.

Glossary

10-Q

A quarterly report required by the U.S. Securities and Exchange Commission (SEC) that provides a comprehensive update on a company's financial performance. (This document provides the detailed financial information for Supernus Pharmaceuticals, Inc. for the specified quarter.)

Product Revenue

Revenue generated from the sale of the company's pharmaceutical products. (This is the primary source of revenue for Supernus and showed significant growth.)

Royalty, License and Other Revenue

Revenue derived from licensing agreements, royalties on sales of partnered products, or other miscellaneous income streams. (This segment experienced a notable decline, impacting the company's overall revenue trend.)

Net Income (Loss)

The profit or loss remaining after all revenues have been accounted for and all expenses have been deducted. (Indicates the company's profitability; Supernus reported a net loss for the quarter.)

Cash and Cash Equivalents

Highly liquid short-term investments that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value. (Represents the company's immediate liquidity available for operations and strategic initiatives.)

Year-Over-Year Comparison

Supernus Pharmaceuticals reported a notable increase in total revenues for the second quarter of 2025, up 20.6% year-over-year, driven by product sales. However, this top-line growth was overshadowed by a shift from net income in the prior year's quarter to a net loss of $1.2 million in Q2 2025. This suggests that operating expenses have outpaced revenue gains, impacting profitability. The company's cash position remains robust at $150.3 million, providing liquidity, but the declining royalty revenue warrants attention.

From the Filing

0001356576-25-000055.txt : 20250805 0001356576-25-000055.hdr.sgml : 20250805 20250805162441 ACCESSION NUMBER: 0001356576-25-000055 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 108 CONFORMED PERIOD OF REPORT: 20250630 FILED AS OF DATE: 20250805 DATE AS OF CHANGE: 20250805 FILER: COMPANY DATA: COMPANY CONFORMED NAME: SUPERNUS PHARMACEUTICALS, INC. CENTRAL INDEX KEY: 0001356576 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-35518 FILM NUMBER: 251185338 BUSINESS ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 BUSINESS PHONE: 301-838-2500 MAIL ADDRESS: STREET 1: 9715 KEY WEST AVENUE CITY: ROCKVILLE STATE: MD ZIP: 20850 FORMER COMPANY: FORMER CONFORMED NAME: SUPERNUS PHARMACEUTICALS INC DATE OF NAME CHANGE: 20060317 10-Q 1 supn-20250630.htm 10-Q supn-20250630 0001356576 false 12-31 2025 Q2 http://fasb.org/us-gaap/2025#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 http://fasb.org/us-gaap/2025#BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 P0Y http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent http://fasb.org/us-gaap/2025#OtherAssetsNoncurrent http://fasb.org/us-gaap/2025#AccountsPayableAndAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2025#AccountsPayableAndAccruedLiabilitiesCurrent http://fasb.org/us-gaap/2025#OperatingLeaseLiabilityNoncurrent http://fasb.org/us-gaap/2025#OperatingLeaseLiabilityNoncurrent 286 xbrli:shares iso4217:USD iso4217:USD xbrli:shares supn:product supn:segment xbrli:pure supn:right iso4217:EUR 0001356576 2025-01-01 2025-06-30 0001356576 2025-07-29 0001356576 2025-06-30 0001356576 2024-12-31 0001356576 us-gaap:ProductMember 2025-04-01 2025-06-30 0001356576 us-gaap:ProductMember 2024-04-01 2024-06-30 0001356576 us-gaap:ProductMember 2025-01-01 2025-06-30 0001356576 us-gaap:ProductMember 2024-01-01 2024-06-30 0001356576 supn:RoyaltyLicenseAndOtherRevenueMember 2025-04-01 2025-06-30 0001356576 supn:RoyaltyLicenseAndOtherRevenueMember 2024-04-01 2024-06-30 0001356576 supn:RoyaltyLicenseAndOtherRevenueMember 2025-01-01 2025-06-30 0001356576 supn:RoyaltyLicenseAndOtherRevenueMember 2024-01-01 2024-06-30 0001356576 2025-04-01 2025-06-30 0001356576 2024-04-01 2024-06-30 0001356576 2024-01-01 2024-06-30 0001356576 us-gaap:CommonStockMember 2024-12-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2024-12-31 0001356576 us-gaap:RetainedEarningsMember 2024-12-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001356576 2025-01-01 2025-03-31 0001356576 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001356576 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-01-01 2025-03-31 0001356576 us-gaap:CommonStockMember 2025-03-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-03-31 0001356576 us-gaap:RetainedEarningsMember 2025-03-31 0001356576 2025-03-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001356576 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001356576 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-04-01 2025-06-30 0001356576 us-gaap:CommonStockMember 2025-06-30 0001356576 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2025-06-30 0001356576 us-gaap:RetainedEarningsMember 2025-06-30 0001356576 us-gaap:CommonStockMember 2023-12-31 0001356576 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001356576 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-12-31 0001356576 u